San Diego-based Zogenix says its late-stage efficacy study of hydrocodone bitartrate (Zohydro) met the company’s intended goal, with patients reporting improved chronic pain relief compared to a placebo. The study also demonstrated that the drug candidate was safe and well-tolerated. If federal drug regulators approve the drug for the U.S. market, Zogenix says it could be the first extended-release hydrocodone treatment available without acetaminophen, which has been linked to an increased risk of liver damage when used in high doses over time. Zogenix has been developing a series of drugs, each paired with its needle-free injector system, and plans to seek regulatory approval for each drug-and-device combo.
By posting a comment, you agree to our terms and conditions.